Volume 3, Issue 12
Colon targeting of ornidazole and curcumin inclusion complex a novel approach in inflammatory bowel disease.
Author: Sukhbir Kaur, Lavleen Kaur
Abstract: The present investigation was planned to formulate tablets of ornidazole and curcumin which are targeting the drug directly to colon for the treatment of inflammatory bowl disease (IBD). Inclusion complex of the drugs with β-cyclodextrin were prepared by kneading method. The 10% coating concentration of eudragit S100 shows the complete release of the drugs to colon for the treatment of IBD. Coating concentration we designed based on the full factorial design. In-vitro release was conducted for all the formulations in USP appratus 1, i.e. basket type for 24 h in different ph resembling different portions of gastro intestinal tract. In vitro dissolution studies, it was found that formulation F4 showed 99.43% of ornidazole in 24 hours and 93.14% of curcumin in 24 hours, which lies in within the acceptance criteria. That study conclude that 10% coating concentration of eudragit S100 shows the complete release of drugs to colon for treatment of inflammatory bowl disease (IBD).
Download Full Article: Click Here
Support Us
If you are interested in supporting our work and would like to contribute, you are welcome to mail me at jpbr.anil@gmail.com or at info@thepharmajournal.com it will be a great help and will surely be appreciated.
